The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy

Molecular Therapy - Oncolytics - Tập 23 - Trang 266-276 - 2021
Kellsye P. Fabian1, James W. Hodge1
1Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, Room 8B09, Bethesda, MD 20892, USA

Tài liệu tham khảo

Abel, 2018, Natural killer cells: Development, maturation, and clinical utilization, Front. Immunol., 9, 1869, 10.3389/fimmu.2018.01869

Lanier, 2008, Up on the tightrope: Natural killer cell activation and inhibition, Nat. Immunol., 9, 495, 10.1038/ni1581

Long, 2013, Controlling natural killer cell responses: Integration of signals for activation and inhibition, Annu. Rev. Immunol., 31, 227, 10.1146/annurev-immunol-020711-075005

Quatrini, 2021, Human NK cells, their receptors and function, Eur. J. Immunol., 51, 1566, 10.1002/eji.202049028

Smyth, 2005, Activation of NK cell cytotoxicity, Mol. Immunol., 42, 501, 10.1016/j.molimm.2004.07.034

Campbell, 2013, Natural killer cell biology: An update and future directions, J. Allergy Clin. Immunol., 132, 536, 10.1016/j.jaci.2013.07.006

Lo Nigro, 2019, NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: Biological evidence and clinical perspectives, Ann. Transl. Med., 7, 105, 10.21037/atm.2019.01.42

Coca, 1997, The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma, Cancer, 79, 2320, 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P

Ishigami, 2000, Prognostic value of intratumoral natural killer cells in gastric carcinoma, Cancer, 88, 577, 10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V

Takanami, 2001, The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma, J. Thorac. Cardiovasc. Surg., 121, 1058, 10.1067/mtc.2001.113026

Villegas, 2002, Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer, Lung Cancer, 35, 23, 10.1016/S0169-5002(01)00292-6

Remark, 2013, Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: Influence of tumor origin, Clin. Cancer Res., 19, 4079, 10.1158/1078-0432.CCR-12-3847

Imai, 2000, Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population, Lancet, 356, 1795, 10.1016/S0140-6736(00)03231-1

Tartter, 1987, The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer, Arch. Surg., 122, 1264, 10.1001/archsurg.1987.01400230050009

Schantz, 1991, Quantitation of natural killer cell function and risk of metastatic poorly differentiated head and neck cancer, Nat. Immun. Cell Growth Regul., 10, 278

Schantz, 1989, Natural killer cells and metastases from pharyngeal carcinoma, Am. J. Surg., 158, 361, 10.1016/0002-9610(89)90134-7

Rosenberg, 1987, A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone, N. Engl. J. Med., 316, 889, 10.1056/NEJM198704093161501

Liu, 2021, NK cell-based cancer immunotherapy: From basic biology to clinical development, J. Hematol. Oncol., 14, 7, 10.1186/s13045-020-01014-w

Wendel, 2021, Arming immune cells for battle: A brief journey through the advancements of T and NK cell immunotherapy, Cancers (Basel), 13, 1481, 10.3390/cancers13061481

Daher, 2021, CAR-NK cells: The next wave of cellular therapy for cancer, Clin. Transl. Immunology, 10, e1274, 10.1002/cti2.1274

Franks, 2020, Natural born killers: NK cells in cancer therapy, Cancers (Basel), 12, E2131, 10.3390/cancers12082131

Klingemann, 2016, Natural killer cells for immunotherapy—Advantages of the NK-92 cell line over blood NK cells, Front. Immunol., 7, 91, 10.3389/fimmu.2016.00091

Gong, 1994, Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells, Leukemia, 8, 652

Maki, 2001, Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92, J. Hematother. Stem Cell Res., 10, 369, 10.1089/152581601750288975

Romanski, 2005, Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia, Exp. Hematol., 33, 344, 10.1016/j.exphem.2004.11.006

Faure, 2002, KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential, J. Immunol., 168, 6208, 10.4049/jimmunol.168.12.6208

Tam, 2003, Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy, Cytotherapy, 5, 259, 10.1080/14653240310001523

Klingemann, 1996, A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood, Biol. Blood Marrow Transplant., 2, 68

Zhang, 2008, Comparison in the effects of IL-2, IL-12, IL-15 and IFNα on gene regulation of granzymes of human NK cell line NK-92, Int. Immunopharmacol., 8, 989, 10.1016/j.intimp.2008.03.001

Törnroos, 2019, Culturing the human natural killer cell line NK-92 in interleukin-2 and interleukin-15—Implications for clinical trials, Anticancer Res., 39, 107, 10.21873/anticanres.13085

Yan, 1998, Antileukemia activity of a natural killer cell line against human leukemias, Clin. Cancer Res., 4, 2859

Swift, 2012, Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model, Haematologica, 97, 1020, 10.3324/haematol.2011.054254

Tam, 1999, Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92, J. Hematother., 8, 281, 10.1089/106161299320316

Arai, 2008, Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: A phase I trial, Cytotherapy, 10, 625, 10.1080/14653240802301872

Tonn, 2013, Treatment of patients with advanced cancer with the natural killer cell line NK-92, Cytotherapy, 15, 1563, 10.1016/j.jcyt.2013.06.017

Boyiadzis, 2017, Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia, Cytotherapy, 19, 1225, 10.1016/j.jcyt.2017.07.008

Williams, 2017, A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy, Oncotarget, 8, 89256, 10.18632/oncotarget.19204

Boissel, 2016, An “off the shelf,” GMP-grade, IL-2-independent NK cell line expressing the high-affinity Fc-receptor to augment antibody therapeutics, Cancer Res., 76, 2302, 10.1158/1538-7445.AM2016-2302

Jochems, 2016, An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele, Oncotarget, 7, 86359, 10.18632/oncotarget.13411

Cartron, 2002, Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene, Blood, 99, 754, 10.1182/blood.V99.3.754

Weng, 2003, Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma, J. Clin. Oncol., 21, 3940, 10.1200/JCO.2003.05.013

Musolino, 2008, Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer, J. Clin. Oncol., 26, 1789, 10.1200/JCO.2007.14.8957

Zhang, 2007, FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab, J. Clin. Oncol., 25, 3712, 10.1200/JCO.2006.08.8021

Bibeau, 2009, Impact of FcγRIIa-FcγRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan, J. Clin. Oncol., 27, 1122, 10.1200/JCO.2008.18.0463

Magnes, 2018, The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab, Pharmacogenomics J., 18, 474, 10.1038/tpj.2017.37

Lehrnbecher, 1999, Variant genotypes of the low-affinity Fcγ receptors in two control populations and a review of low-affinity Fcγ receptor polymorphisms in control and disease populations, Blood, 94, 4220, 10.1182/blood.V94.12.4220.424k08_4220_4232

Gómez Román, 2014, Antibody-dependent cellular cytotoxicity (ADCC), 1

Kistler, 2020, Safety and efficacy from first-in-human immunotherapy combining NK and T cell activation with off-the-shelf high-affinity CD16 NK cell line (haNK) in patients with 2nd-line or greater metastatic triple-negative breast cancer (TNBC), Cancer Res., 80, P5-04-02, 10.1158/1538-7445.SABCS19-P5-04-02

Kanwal, 2021, Relapsed/refractory non-Hodgkin lymphoma: engineering T-cells to express chimeric antigen receptors (CARs), a salvage?, Cureus, 13, e16307

George, 2021, Emerging targets and cellular therapy for relapsed refractory multiple myeloma: A systematic review, Clin. Lymphoma Myeloma Leuk., 10.1016/j.clml.2021.06.003

D’Aloia, 2018, CAR-T cells: The long and winding road to solid tumors, Cell Death Dis., 9, 282, 10.1038/s41419-018-0278-6

Ichiki, 2006, T cell immunity and graft-versus-host disease (GVHD), Autoimmun. Rev., 5, 1, 10.1016/j.autrev.2005.02.006

Gust, 2017, Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells, Cancer Discov., 7, 1404, 10.1158/2159-8290.CD-17-0698

Brudno, 2016, Toxicities of chimeric antigen receptor T cells: Recognition and management, Blood, 127, 3321, 10.1182/blood-2016-04-703751

Klingemann, 2014, Are natural killer cells superior CAR drivers?, OncoImmunology, 3, e28147, 10.4161/onci.28147

Miller, 2005, Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer, Blood, 105, 3051, 10.1182/blood-2004-07-2974

Shaffer, 2016, Phase II study of haploidentical natural killer cell infusion for treatment of relapsed or persistent myeloid malignancies following allogeneic hematopoietic cell transplantation, Biol. Blood Marrow Transplant., 22, 705, 10.1016/j.bbmt.2015.12.028

Hu, 2018, Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy, Acta Pharmacol. Sin., 39, 167, 10.1038/aps.2017.125

Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial, Lancet, 385, 517, 10.1016/S0140-6736(14)61403-3

Teachey, 2016, Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia, Cancer Discov., 6, 664, 10.1158/2159-8290.CD-16-0040

Zhang, 2017, Chimeric antigen receptor-engineered NK-92 cells: An off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity, Front. Immunol., 8, 533, 10.3389/fimmu.2017.00533

Kalos, 2011, T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia, Sci. Transl. Med., 3, 95ra73, 10.1126/scitranslmed.3002842

Morgan, 2010, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2, Mol. Ther., 18, 843, 10.1038/mt.2010.24

Fabian, 2020, PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations, J. Immunother. Cancer, 8, e000450, 10.1136/jitc-2019-000450

Chen, 2018, Driving CARs on the uneven road of antigen heterogeneity in solid tumors, Curr. Opin. Immunol., 51, 103, 10.1016/j.coi.2018.03.002

Dotti, 2014, Design and development of therapies using chimeric antigen receptor-expressing T cells, Immunol. Rev., 257, 107, 10.1111/imr.12131

Guedan, 2018, Engineering and design of chimeric antigen receptors, Mol. Ther. Methods Clin. Dev., 12, 145, 10.1016/j.omtm.2018.12.009

Töpfer, 2015, DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy, J. Immunol., 194, 3201, 10.4049/jimmunol.1400330

Müller, 2015, Engineering NK cells modified with an EGFRvIII-specific chimeric antigen receptor to overexpress CXCR4 improves immunotherapy of CXCL12/SDF-1α-secreting glioblastoma, J. Immunother., 38, 197, 10.1097/CJI.0000000000000082

Clémenceau, 2015, In vitro and in vivo comparison of lymphocytes transduced with a human CD16 or with a chimeric antigen receptor reveals potential off-target interactions due to the IgG2 CH2-CH3 CAR-spacer, J. Immunol. Res., 2015, 482089

Gong, 2021, Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy, J. Hematol. Oncol., 14, 73, 10.1186/s13045-021-01083-5

Schönfeld, 2015, Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor, Mol. Ther., 23, 330, 10.1038/mt.2014.219

Suerth, 2016, Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors, J. Mol. Med. (Berl.), 94, 83, 10.1007/s00109-015-1327-6

Boissel, 2012, Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens, Leuk. Lymphoma, 53, 958, 10.3109/10428194.2011.634048

Boissel, 2009, Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells, Leuk. Res., 33, 1255, 10.1016/j.leukres.2008.11.024

Uherek, 2002, Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction, Blood, 100, 1265, 10.1182/blood.V100.4.1265.h81602001265_1265_1273

Wong, 2014, Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates, Ann. Transl. Med., 2, 122

Liu, 2017, Driving better and safer HER2-specific CARs for cancer therapy, Oncotarget, 8, 62730, 10.18632/oncotarget.17528

Daldrup-Link, 2005, In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging, Eur. Radiol., 15, 4, 10.1007/s00330-004-2526-7

Meier, 2008, Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors, Nucl. Med. Biol., 35, 579, 10.1016/j.nucmedbio.2008.02.006

Alkins, 2013, Focused ultrasound delivers targeted immune cells to metastatic brain tumors, Cancer Res., 73, 1892, 10.1158/0008-5472.CAN-12-2609

Zhang, 2015, ErbB2/HER2-specific NK cells for targeted therapy of glioblastoma, J. Natl. Cancer Inst., 108, djv375

Liu, 2015, Specific growth inhibition of ErbB2-expressing human breast cancer cells by genetically modified NK-92 cells, Oncol. Rep., 33, 95

Müller, 2008, Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells, Cancer Immunol. Immunother., 57, 411, 10.1007/s00262-007-0383-3

Boissel, 2013, Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity, OncoImmunology, 2, e26527, 10.4161/onci.26527

Oelsner, 2017, Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma, Cytotherapy, 19, 235, 10.1016/j.jcyt.2016.10.009

Liu, 2020, Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19+ malignancy in a mouse model, Cytotherapy, 22, 552, 10.1016/j.jcyt.2020.06.003

Jiang, 2014, Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells, Mol. Oncol., 8, 297, 10.1016/j.molonc.2013.12.001

Chu, 2014, CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma, Leukemia, 28, 917, 10.1038/leu.2013.279

Chen, 2016, Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies, Oncotarget, 7, 56219, 10.18632/oncotarget.11019

Chen, 2017, Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor, Leukemia, 31, 2151, 10.1038/leu.2017.8

Xu, 2019, 2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies, J. Hematol. Oncol., 12, 49, 10.1186/s13045-019-0732-7

You, 2019, A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia, Am. J. Cancer Res., 9, 64

Han, 2015, CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells, Sci. Rep., 5, 11483, 10.1038/srep11483

Genßler, 2015, Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival, OncoImmunology, 5, e1119354, 10.1080/2162402X.2015.1119354

Zhang, 2017, Synergistic effects of cabozantinib and EGFR-specific CAR-NK-92 cells in renal cell carcinoma, J. Immunol. Res., 2017, 6915912

Zhang, 2018, Combination therapy with EpCAM-CAR-NK-92 cells and regorafenib against human colorectal cancer models, J. Immunol. Res., 2018, 4263520

Seidel, 2015, Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma, Cancer Immunol. Immunother., 64, 621, 10.1007/s00262-015-1669-5

Yu, 2018, Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma, Mol. Ther., 26, 366, 10.1016/j.ymthe.2017.12.012

Cao, 2020, Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer, Biochem. Biophys. Res. Commun., 524, 96, 10.1016/j.bbrc.2020.01.053

Montagner, 2020, Anti-PSMA CAR-engineered NK-92 cells: An off-the-shelf cell therapy for prostate cancer, Cells, 9, E1382, 10.3390/cells9061382

Zhang, 2013, Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody, Immunol. Cell Biol., 91, 615, 10.1038/icb.2013.45

Zhao, 2015, Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential, Leukemia, 29, 2238, 10.1038/leu.2015.125

Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, 12, 252, 10.1038/nrc3239

Yang, 2020, Targeting B7-H3 immune checkpoint with chimeric antigen receptor-engineered natural killer cells exhibits potent cytotoxicity against non-small cell lung cancer, Front. Pharmacol., 11, 1089, 10.3389/fphar.2020.01089

Robbins, 2020, Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells, eLife, 9, e54854, 10.7554/eLife.54854

Tang, 2018, First-in-man clinical trial of CAR NK-92 cells: Safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia, Am. J. Cancer Res., 8, 1083

Tambaro, 2021, Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia, Leukemia, 10.1038/s41375-021-01232-2

Burger, 2019, CAR-engineered NK cells for the treatment of glioblastoma: Turning innate effectors into precision tools for cancer immunotherapy, Front. Immunol., 10, 2683, 10.3389/fimmu.2019.02683

Nath, 2014, MUC1: A multifaceted oncoprotein with a key role in cancer progression, Trends Mol. Med., 20, 332, 10.1016/j.molmed.2014.02.007

Li, 2019, Phase I clinical trial with PD-1/MUC1 CAR-pNK92 immunotherapy, Cancer Immunol. Res., 7, A014, 10.1158/2326-6074.CRICIMTEATIAACR18-A014

Adams, 2021, Sacituzumab govitecan and trastuzumab deruxtecan: Two new antibody-drug conjugates in the breast cancer treatment landscape, ESMO Open, 6, 100204, 10.1016/j.esmoop.2021.100204

Hermanson, 2015, Utilizing chimeric antigen receptors to direct natural killer cell activity, Front. Immunol., 6, 195, 10.3389/fimmu.2015.00195

Wang, 2017, Augmented anti-tumor activity of NK-92 cells expressing chimeric receptors of TGF-βR II and NKG2D, Cancer Immunol. Immunother., 66, 537, 10.1007/s00262-017-1959-1

Thông tin
Thông tin xuất bản

Molecular Therapy - Oncolytics

Tập 23

266-276

Thông tin tác giả